# A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

> **NCT03227861** · PHASE3 · COMPLETED · sponsor: **Janssen Scientific Affairs, LLC** · enrollment: 109 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC

## Key facts

- **NCT ID:** NCT03227861
- **Lead sponsor:** Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2019-01-03
- **Final completion:** 2019-09-04
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227861, "A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03227861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*